1. A novel small molecule tyrosine kinase inhibitor (GUtinib) preferentially targets discoidin domain receptors and reduces toxic proteins in neurodegeneration. (October 2020) Authors: Moussa, C.; Torres-Yaghi, Y.; Pagan, F. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions. (October 2020) Authors: Pagan, F.; Jost, W.H.; Friedman, A.; Michel, O.; Oehlwein, C.; Slawek, J.; Bogucki, A.; Ochudlo, S.; Banach, M.; Flatau-Baqué, B.; Csikós, J.; Blitzer, A. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cardiac dysautonomia in Parkinson's Disease. (October 2020) Authors: Carwin, A.; Miri, S.; Nakano, S.; Anjum, M.; Mundel, E.; Starr, J.; Marsh, C.; Wilmarth, B.; Arellano, M.; Howard, H.; Hebron, M.; Torres-Yaghi, Y.; Moussa, C.; Pagan, F. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Current ICD-10-CM coding does not adequately reflect Parkinson's disease with motor complications. (October 2020) Authors: Dashtipour, K.; Bahroo, L.; Pagan, F.; Torres-Yaghi, Y.; Isaacson, S. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea. (October 2020) Authors: Pagan, F.; Lew, M.; Pahwa, R.; Clinch, T.; Kasibhatla, C.; Isaacson, S. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the CSF of individuals with Parkinson's disease. (October 2020) Authors: Torres-Yaghi, Y.; Pagan, F.; Moussa, C. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Nilotinib increases brain dopamine and lowers CSF tau and oligomeric alpha-Synuclein in Parkinson's disease. (October 2020) Authors: Moussa, C.; Torres-Yaghi, Y.; Pagan, F. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Nilotinib is reasonably safe and may halt the disease progression in moderately severe Parkinson's disease patients. (October 2020) Authors: Pagan, F.; Torres-Yaghi, Y.; Moussa, C. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. (March 2018) Authors: Casadei Gardini, A.; Passardi, A.; Fornaro, L.; Rosetti, P.; Valgiusti, M.; Ruscelli, S.; Monti, M.; Casadei, C.; Pagan, F.; Frassineti, G.L. Journal: Critical reviews in oncology/hematology Issue: Volume 123(2018) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗